vs
Side-by-side financial comparison of Gilead Sciences (GILD) and IMPERIAL OIL LTD (IMO). Click either name above to swap in a different company.
IMPERIAL OIL LTD is the larger business by last-quarter revenue ($8.2B vs $7.9B, roughly 1.0× Gilead Sciences). Gilead Sciences runs the higher net margin — 27.5% vs 4.4%, a 23.2% gap on every dollar of revenue. On growth, Gilead Sciences posted the faster year-over-year revenue change (4.7% vs -10.5%). Gilead Sciences produced more free cash flow last quarter ($3.1B vs $938.8M). Over the past eight quarters, Gilead Sciences's revenue compounded faster (8.9% CAGR vs -4.2%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Imperial Oil Limited is a Canadian petroleum company. It is Canada's second-largest integrated oil company that is also occasionally known as Imperial Esso. It is majority-owned by American oil company ExxonMobil, with a 69.6% ownership stake in the company. It is a producer of crude oil, diluted bitumen, and natural gas. Imperial Oil is one of Canada's major petroleum refiners and petrochemical producers. It supplies Esso-brand service stations.
GILD vs IMO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $8.2B |
| Net Profit | $2.2B | $359.2M |
| Gross Margin | 79.5% | — |
| Operating Margin | 25.0% | 5.6% |
| Net Margin | 27.5% | 4.4% |
| Revenue YoY | 4.7% | -10.5% |
| Net Profit YoY | 22.4% | -59.8% |
| EPS (diluted) | $1.75 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.9B | $8.2B | ||
| Q3 25 | $7.8B | $8.8B | ||
| Q2 25 | $7.1B | $8.2B | ||
| Q1 25 | $6.7B | $9.1B | ||
| Q4 24 | $7.6B | $9.2B | ||
| Q3 24 | $7.5B | $9.7B | ||
| Q2 24 | $7.0B | $9.8B | ||
| Q1 24 | $6.7B | $9.0B |
| Q4 25 | $2.2B | $359.2M | ||
| Q3 25 | $3.1B | $393.5M | ||
| Q2 25 | $2.0B | $692.8M | ||
| Q1 25 | $1.3B | $940.2M | ||
| Q4 24 | $1.8B | $894.3M | ||
| Q3 24 | $1.3B | $903.0M | ||
| Q2 24 | $1.6B | $827.1M | ||
| Q1 24 | $-4.2B | $872.4M |
| Q4 25 | 79.5% | — | ||
| Q3 25 | 79.8% | — | ||
| Q2 25 | 78.8% | — | ||
| Q1 25 | 76.9% | — | ||
| Q4 24 | 79.1% | — | ||
| Q3 24 | 79.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.8% | — |
| Q4 25 | 25.0% | 5.6% | ||
| Q3 25 | 42.8% | 5.8% | ||
| Q2 25 | 34.9% | 11.1% | ||
| Q1 25 | 33.6% | 13.5% | ||
| Q4 24 | 32.4% | 12.5% | ||
| Q3 24 | 11.8% | 12.1% | ||
| Q2 24 | 38.0% | 11.1% | ||
| Q1 24 | -64.6% | 12.8% |
| Q4 25 | 27.5% | 4.4% | ||
| Q3 25 | 39.3% | 4.5% | ||
| Q2 25 | 27.7% | 8.4% | ||
| Q1 25 | 19.7% | 10.3% | ||
| Q4 24 | 23.6% | 9.7% | ||
| Q3 24 | 16.6% | 9.3% | ||
| Q2 24 | 23.2% | 8.5% | ||
| Q1 24 | -62.4% | 9.7% |
| Q4 25 | $1.75 | — | ||
| Q3 25 | $2.43 | — | ||
| Q2 25 | $1.56 | — | ||
| Q1 25 | $1.04 | — | ||
| Q4 24 | $1.43 | — | ||
| Q3 24 | $1.00 | — | ||
| Q2 24 | $1.29 | — | ||
| Q1 24 | $-3.34 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | $833.7M |
| Total DebtLower is stronger | $24.9B | $2.9B |
| Stockholders' EquityBook value | $22.7B | $16.2B |
| Total Assets | $59.0B | $30.9B |
| Debt / EquityLower = less leverage | 1.10× | 0.18× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.0M | $833.7M | ||
| Q3 25 | $19.0M | $1.4B | ||
| Q2 25 | $69.0M | $1.7B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $714.7M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $858.5M |
| Q4 25 | $24.9B | $2.9B | ||
| Q3 25 | $24.9B | $2.9B | ||
| Q2 25 | $24.9B | $2.9B | ||
| Q1 25 | $25.0B | $2.9B | ||
| Q4 24 | $26.7B | $2.9B | ||
| Q3 24 | $23.2B | $2.9B | ||
| Q2 24 | $23.3B | $2.9B | ||
| Q1 24 | $25.2B | $2.9B |
| Q4 25 | $22.7B | $16.2B | ||
| Q3 25 | $21.5B | $17.3B | ||
| Q2 25 | $19.7B | $18.2B | ||
| Q1 25 | $19.2B | $17.8B | ||
| Q4 24 | $19.3B | $17.1B | ||
| Q3 24 | $18.5B | $17.3B | ||
| Q2 24 | $18.3B | $17.5B | ||
| Q1 24 | $17.5B | $16.9B |
| Q4 25 | $59.0B | $30.9B | ||
| Q3 25 | $58.5B | $31.4B | ||
| Q2 25 | $55.7B | $32.2B | ||
| Q1 25 | $56.4B | $32.0B | ||
| Q4 24 | $59.0B | $31.3B | ||
| Q3 24 | $54.5B | $31.0B | ||
| Q2 24 | $53.6B | $32.2B | ||
| Q1 24 | $56.3B | $31.0B |
| Q4 25 | 1.10× | 0.18× | ||
| Q3 25 | 1.16× | 0.17× | ||
| Q2 25 | 1.27× | 0.16× | ||
| Q1 25 | 1.30× | 0.16× | ||
| Q4 24 | 1.38× | 0.17× | ||
| Q3 24 | 1.26× | 0.17× | ||
| Q2 24 | 1.28× | 0.17× | ||
| Q1 24 | 1.44× | 0.17× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $1.4B |
| Free Cash FlowOCF − Capex | $3.1B | $938.8M |
| FCF MarginFCF / Revenue | 39.4% | 11.4% |
| Capex IntensityCapex / Revenue | 2.6% | 5.6% |
| Cash ConversionOCF / Net Profit | 1.52× | 3.90× |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | $3.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.3B | $1.4B | ||
| Q3 25 | $4.1B | $1.3B | ||
| Q2 25 | $827.0M | $1.1B | ||
| Q1 25 | $1.8B | $1.1B | ||
| Q4 24 | $3.0B | $1.3B | ||
| Q3 24 | $4.3B | $1.1B | ||
| Q2 24 | $1.3B | $1.2B | ||
| Q1 24 | $2.2B | $785.5M |
| Q4 25 | $3.1B | $938.8M | ||
| Q3 25 | $4.0B | $944.6M | ||
| Q2 25 | $720.0M | $725.6M | ||
| Q1 25 | $1.7B | $824.2M | ||
| Q4 24 | $2.8B | $997.2M | ||
| Q3 24 | $4.2B | $730.7M | ||
| Q2 24 | $1.2B | $852.6M | ||
| Q1 24 | $2.1B | $422.7M |
| Q4 25 | 39.4% | 11.4% | ||
| Q3 25 | 51.0% | 10.7% | ||
| Q2 25 | 10.2% | 8.8% | ||
| Q1 25 | 24.8% | 9.0% | ||
| Q4 24 | 37.4% | 10.8% | ||
| Q3 24 | 55.2% | 7.5% | ||
| Q2 24 | 17.2% | 8.7% | ||
| Q1 24 | 31.6% | 4.7% |
| Q4 25 | 2.6% | 5.6% | ||
| Q3 25 | 1.9% | 4.2% | ||
| Q2 25 | 1.5% | 4.2% | ||
| Q1 25 | 1.6% | 3.2% | ||
| Q4 24 | 1.9% | 3.4% | ||
| Q3 24 | 1.9% | 3.7% | ||
| Q2 24 | 1.9% | 3.4% | ||
| Q1 24 | 1.6% | 4.0% |
| Q4 25 | 1.52× | 3.90× | ||
| Q3 25 | 1.35× | 3.34× | ||
| Q2 25 | 0.42× | 1.54× | ||
| Q1 25 | 1.34× | 1.19× | ||
| Q4 24 | 1.67× | 1.46× | ||
| Q3 24 | 3.44× | 1.20× | ||
| Q2 24 | 0.82× | 1.44× | ||
| Q1 24 | — | 0.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
IMO
Segment breakdown not available.
